Fosravuconazole L-lysine ethanolate

Cat. No.: HY-16779B

CAS No.: 914361-45-8

Molecular Formula: $C_{31}H_{40}F_2N_7O_8PS$

Molecular Weight: 739.73

Target: Fungal; Parasite

Pathway: Anti-infection

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 200 mg/mL (270.37 mM; Need ultrasonic)
DMSO : 50 mg/mL (67.59 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.3518 mL	6.7592 mL	13.5184 mL
	5 mM	0.2704 mL	1.3518 mL	2.7037 mL
	10 mM	0.1352 mL	0.6759 mL	1.3518 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 50 mg/mL (67.59 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3].

In Vitro

Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus , and Trichophyton species[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain)[3].
Dosage:	10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg
Administration:	Oral administration; daily; for 20 days
Result:	Suppressed the parasitemia and prevented death.

REFERENCES

[1]. Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159.

[2]. Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278.

[3]. Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA